Loading...

OPTIMIZING NON-ADDICTIVE DRUG DELIVERY

IN THE MANAGEMENT OF PAIN AND CNS DISORDERS, INCLUDING RARE AND ORPHAN DISEASES

Virpax Pharmaceuticals specializes in developing novel and proprietary drug-delivery platforms across various pain and CNS disorder indications to enhance compliance and to optimize the efficacy of each product candidate.

Our transforming drug-delivery platforms and their targeted drug-releasing capabilities have been developed to optimize the efficacy of our non-addictive pain management pipeline and our CNS disorder pipeline.

Virpax is developing non-addictive pain treatment options that allow for more individualized patient care. More treatment options may help increase better health outcomes; including better, rehabilitation, post-surgery care, functionality, quality of life and may help patients get back to work.

Virpax is publicly traded on

(Nasdaq: VRPX)

Targeting pain at its source

Virpax® Pharmaceuticals is a publicly held specialty pharmaceutical company located in Berwyn, PA and is focused on advancing the development and worldwide commercialization of its non-addictive pain and neurological disorder pipeline.

View our presentation

OPTIMIZING NON-ADDICTIVE DRUG DELIVERY

IN THE TREATMENT OF PAIN AND CNS DISORDERS, INCLUDING RARE AND ORPHAN DISEASES

Probudur injection icon

Probudur™

Injectable liposomal hydrogel Bupivacaine

Probudur is the only liposomal hydro-gel bupivacaine formulation that has demonstrated 96 hours pain control administering a single injection at the wound site in head to head in-vivo studies.

More about Probudur
Envelta spray icon

Envelta™

Molecular Envelope Enkephalin Powder

Envelta is a patented intranasal enkephalin powder formulation being studied to manage severe post cancer pain and non-cancer pain without the concerns of dependence, respiratory depression, and tolerance compared to morphine.

More about Envelta
VRP324 spray icon

NobrXiol™

Molecular Envelope Cannabidiol Powder

NobrXiol is a patented pharmaceutical-grade cannabidiol intranasal spray powder being developed to manage Rare Pediatric Epilepsy (Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome).

More about NobrXiol

We are pairing effective pain and CNS treatments with our transforming drug-delivery platforms

Virpax’s proprietary Rx pipeline is well positioned to meet unmet needs in multi-billion dollar markets.

View our pipeline

We’re seeking global partners to sublicense OTC, Device, and Animal Health

We engaged Destum Partners to help us connect the world with promising products.

VIEW OUR SUBLICENSING PIPELINE

Recent Press Releases

  • January 31, 2023

  • January 18, 2023

  • January 10, 2023

  • January 4, 2023

VIEW MORE

Recent Media

  • Jan 4, 2023

  • Jul 28, 2022

  • Jun 27, 2022

  • Apr 27, 2022

VIEW MORE

OUR MISSION

Our mission is to use our proprietary delivery platforms to optimize the efficacy of our non-addictive post operative pain, severe pain and CNS disorder product candidates.

We want to provide healthcare professionals and patients with effective solutions to manage pain and neurological disorders worldwide, including rare and orphan diseases.

“We’ve continued to support development of novel non-addictive treatments for pain, including non-opioid analgesics and medical devices.”

ROBERT CALIFF

FDA Commissioner
CalloutWE'RE WORKING TOADVANCE NON-ADDICTIVE PAIN MANAGEMENT WORLDWIDE

Experienced

executive leadership
Learn more

Robust

pipeline
Learn more
virpax pharma pain management mission

Explore our

Mission

new pain management solutions

Discover our

Products

Pain Management - Team

Meet our

Team

virpax pharmaceutical contact

Let’s

Connect